symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BLTE,32.99,0,87959,898294607,0,11.0-36.7,0.065,"Belite Bio, Inc",USD,0001889109,US07782B1044,07782B104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://belitebio.com,"Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.","Dr. Yu-Hsin  Lin M.B.A., Ph.D.",Healthcare,US,5,858-246-6240,5820 Oberlin Drive,San Diego,CA,92121,,0,https://financialmodelingprep.com/image-stock/BLTE.png,2022-04-29,False,False,True,False,False
